Opinion|Videos|September 17, 2024
Management of Oral Toxcities associated with GPRC5D Bispecifics Nail
Author(s)Larysa Sanchez, MD, Samantha Shenoy, MSN, NP
Experts discuss the adverse events observed with talquetamab, including oral toxicities and skin and nail issues, and how these are managed.
Advertisement
Episodes in this series
Video content above is prompted by the following:
What are some adverse events (AEs) observed with talquetamab and how are these managed?
- Please discuss management of oral toxicities.
- Please discuss management of skin and nail AEs.
Advertisement
Related to this article
Oncology nurses play a key role guiding patients about AI breast cancer risk assessment tools, dynamic re-testing, and individualized screening plans.
Dana-Farber nurse practitioners outline ADC patient selection, sequencing, ILD surveillance, and patient education from JADPRO Live 2026.
Brianne Whitley, CNP, of Dana-Farber, shares strategies for hot flashes, sexual health, survivorship planning, and clinical trial access for men.
The approval covers IV and subcutaneous pembrolizumab and raises the TMB-H threshold from 10 to 13 mutations/megabase.
The oral, once-daily EGFR inhibitor is now in specialty distribution for patients whose disease progressed after platinum-based chemotherapy.
Explore how nurses support kidney transplant candidates diagnosed with renal cell carcinoma, covering early detection, treatment options, and care.
Dana-Farber's Brianne Whitley, CNP, details red-flag symptoms, ER-positive biology, and why every man with breast cancer needs a genetic referral.
European survey reveals how oncology nurses manage complex multiple myeloma care amid time and resource constraints.
Advertisement
Advertisement
Trending on Oncology Nursing News
1
AI Breast Cancer Risk Models Guide Triage and Nurse-Led Patient Counseling
2
Sunvozertinib Now Available in US for Pretreated EGFR Exon 20+ NSCLC
3
What Oncology Nurses Need to Know About ADCs in Breast Cancer
4
FDA Grants Traditional Approval to Pembrolizumab in TMB-H Solid Tumors
5